GLP-1's Effect on Cardiac Parameters and Mesenteric Blood Flow
November 19, 2013 updated by: MD ph.d. Lasse Bremholm, Zealand University Hospital
GLP-1's Influence on Intestinal Blood Flow
to investigate the effect of the human incretin hormone GLP-1 on mesenteric blood flow and cardiac parameters
Study Overview
Status
Unknown
Conditions
Detailed Description
to investigate the effect of the human incretin hormone GLP-1 on mesenteric blood flow and cardiac parameters, in healthy subjects, 4 arms, task force monitor
Study Type
Interventional
Enrollment (Anticipated)
8
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
State...
-
Køge, State..., Denmark, 4600
- Recruiting
- Køge Hospital
-
Contact:
- lasse bremholm, MD, ph.d.
- Phone Number: 004560927874
- Email: lassebremholm@dadlnet.dk
-
Principal Investigator:
- Lasse Bremholm, MD, ph.d.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 76 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- healthy subjects
Exclusion Criteria:
- medical conditions
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: GLP-1
1,5 nmol/kg,GLP-1 sc injection
|
|
|
Active Comparator: GLP-1 9-36amide
1,5 nmol/kg GLP-1 9-36amide, sc injection
|
Other Names:
|
|
Active Comparator: Exendin-4
Exendin-4 ;10 ug,sc injection
|
Other Names:
|
|
Placebo Comparator: isotonic saline
2 ml of isotonic saline, sc injection
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
blood flow
Time Frame: with in 120 minutes
|
blood flow change measured by ultra sound
|
with in 120 minutes
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
cardiac parameters
Time Frame: with in 120 minutes
|
measure of cardiac change with task force monitor
|
with in 120 minutes
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Lasse Bremholm, MD, ph.d., Køge Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2013
Primary Completion (Anticipated)
June 1, 2014
Study Completion (Anticipated)
December 1, 2014
Study Registration Dates
First Submitted
November 13, 2013
First Submitted That Met QC Criteria
November 19, 2013
First Posted (Estimate)
November 20, 2013
Study Record Updates
Last Update Posted (Estimate)
November 20, 2013
Last Update Submitted That Met QC Criteria
November 19, 2013
Last Verified
November 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2013.GLP-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.